Evermine50 - Drug Eluting Stent (DES) - Meril Vascular Intervention

on

EVERMINE50

Breakthrough in DES Technology:
  • Ultra-low strut thickness of 50μm for promoting early vascular healing
  • Variable strut width and variable crown design to ensure adequate radial strength of 1.1bar*
  • Hybrid cell stent design: Open cells in the middle of the stent for side-branch access and closed cell design on ends for optimal scaffolding and conformability
  • Clinically established drug everolimus with biodegradable polymer for proven clinical safety & long term efficacy
*Bench test data on file at Meril Life Sciences

Visit our website to learn more about the product.

Comments

Post a Comment